Keryx Biopharma (KERX) reported earnings on Wed 1 March 17 (b/o)

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.
Sector: Healthcare
Industry: Biotechnology
Founded in 1997
Headquartered in Boston, Massachusetts.
Full Time Employees: 210
http://www.keryx.com

** charts after earnings **

  

Keryx Biopharma misses by $0.07, misses on revs:

• Reports Q4 (Dec) loss of $0.32 per share, $0.07 worse than the Capital IQ Consensus of ($0.25); revenues rose 64.9% year/year to $9.53 mln (in-line with 1/9 pre-announcement) vs the $9.65 mln Capital IQ Consensus.
• Keryx reported today that in January 2017 Auryxia prescriptions increased to approximately 4,650, or 3.3 percent from December 2016, while the overall market for phosphate binder prescriptions declined by 2.6 percent.
• Approximately 8,700 prescriptions for Auryxia were reported in the fourth quarter of 2016, which included approximately 4,500 prescriptions reported for the month of December, the first full month of sales post resupply of Auryxia. This compares to approximately 5,000 prescriptions for the month of July 2016, the last full month of sales prior to the supply interruption.
• Cash and cash equivalents as of December 31, 2016 totaled approximately $111.8 million.
• "We are off to a very good start in 2017 with Auryxia in the dialysis patient population..During a period when the phosphate binder market declined, Auryxia prescriptions grew to approximately 4,650 in January, an increase of 3.3 percent from the approximate 4,500 prescriptions reported in December 2016...we look forward to important milestones over the year that would mark continued progress toward our goal of maximizing Auryxia's potential. These include continued growth in the U.S. dialysis market, acceptance and assignment of a target review date for the supplemental new drug application submitted in January to the U.S. FDA to expand the indication of Auryxia for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent chronic kidney disease, and the subsequent approval and launch in late 2017. If approved for this indication, Auryxia could be the first FDA-approved oral medicine to treat IDA in this patient population."